计算溶液所需的质量、体积或浓度。
Ropidoxuridine (IPdR) is a novel orally available, halogenated thymidine analog and is a potential radiosensitizer for use in human tumors.
In Vitro
Ropidoxuridine is an orally bioavailable pro-drug of IUdR (5-iodo-2'-deoxyuridine). Ropidoxuridine demonstrates strong synergy effects with Alisertib at clinically relevant concentrations. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
In an orthotopic tumor model, Ropidoxuridine (750 mg/kg/day) and Alisertib (30 mg/kg/day) demonstrate strong synergy effects . MCE has not independently confirmed the accuracy of these methods. They are for reference only.